Last reviewed · How we verify
NCT07363265
Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
Phase 2 trial testing LP-005 Injection in Complement-mediated Renal Diseases in 46 participants. Not yet recruiting.
2 August 2028
Quick facts
| Lead sponsor | Longbio Pharma |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 46 |
| Start date | 2 February 2026 |
| Primary completion | 2 August 2028 |
| Estimated completion | 2 May 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- LP-005 Injection — full drug profile →
Conditions studied
- Complement-mediated Renal Diseases — all drugs for Complement-mediated Renal Diseases →
Sponsor
Longbio Pharma — full company profile →
Who can join
Adults 18 to 65, any sex, with Complement-mediated Renal Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, open-label, proof-of-concept, phase Ⅱ adaptive basket clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of LP-005 Injection as add-on therapy to standard treatment in patients with complement-mediated renal diseases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07363265
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of LP-005 Injection
Trials testing the same drug.
- NCT07266155 — Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) · Phase 2 · not yet recruiting
- NCT07212426 — Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients. · Phase 2 · active not recruiting
Other Longbio Pharma trials
Trials by the same sponsor.
- NCT07313917 — A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyp · Phase 2 · not yet recruiting
- NCT07266155 — Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) · Phase 2 · not yet recruiting
- NCT07148557 — A Study of Single Dose of LP-003 in Adolescent Subjects · Phase 1, PHASE2 · active not recruiting
- NCT07342803 — Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients · Phase 2 · recruiting
- NCT07212426 — Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients. · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07363265 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Longbio Pharma
- Last refreshed: 23 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07363265.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing